{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', \"INVESTIGATOR'S AGREEMENT\", 'I have read and understand the contents of this clinical protocol for Study KCP-330-023 dated', '17 August 2018 and will adhere to the study requirements as presented, including all statements', 'regarding confidentiality. In addition, I will conduct the Study in accordance with current Good', 'Clinical Practice, ICH E6, and applicable FDA regulatory requirements.', 'Printed Name of Investigator', 'Signature of Investigator', 'Institution', 'Date', 'Confidential', 'Page 3', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES', '1.', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', '12', '2.', 'PROTOCOL SYNOPSIS', '17', '3.', 'STUDY SCHEMATICS AND SCHEDULE OF ASSESSMENTS AND', 'DOSING FOR STUDY KCP-330-023', '22', '3.1.', 'Schedules of Visits for In-clinic Dosing and MM Evaluations', '29', '3.2.', 'Dose Schedules', '31', '4.', 'INTRODUCTION', '35', '4.1.', 'Multiple Myeloma', '35', '4.1.1.', 'Disease Background', '35', '4.1.2.', 'MM Treatment', '35', '4.2.', 'Selinexor', '35', '4.2.1.', 'Selinexor Mechanism of Action', '35', '4.2.2.', 'Selinexor Pharmacodynamics and Dosing Frequency', '36', '4.2.3.', 'Selinexor Pharmacokinetics', '36', '4.2.4.', 'Selinexor Metabolism/Drug-drug Interactions', '37', '4.2.5.', 'Selinexor Nonclinical Combination with Dexamethasone and Proteasome', 'Inhibitors', '37', '4.2.6.', 'Overall Clinical Experience with Selinexor', '38', '4.2.6.1.', 'Study KCP-330-017 (STOMP)', '39', '4.2.7.', 'Potential Risks of Selinexor', '40', '4.2.7.1.', 'Reproductive Risks for Selinexor', '41', '4.3.', 'Bortezomib and Dexamethasone (Vd)', '41', '4.4.', 'Study and Dose Rationale', '41', '4.4.1.', 'Study Rationale', '41', '4.4.2.', 'Dose Rationale', '42', '4.4.2.1.', 'Bortezomib QW Dose Rationale', '43', '5.', 'STUDY OBJECTIVES AND ENDPOINTS', '44', '5.1.', 'Objectives', '44', '5.1.1.', 'Primary Objective', '44', '5.1.2.', 'Secondary Objectives', '44', '5.1.3.', 'Exploratory Objectives', '44', '5.1.4.', 'Pharmacokinetic Objective', '45', 'Confidential', 'Page 4', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '5.2.', 'Endpoints', '45', '5.2.1.', 'Primary Endpoint', '45', '5.2.2.', 'Secondary Efficacy Endpoints', '45', '5.2.2.1.', 'Key Secondary Efficacy Endpoints', '45', '5.2.2.2.', 'Non-Key Secondary Efficacy Endpoints', '45', '5.2.3.', 'Secondary Safety Endpoints', '46', '5.2.3.1.', 'Key Secondary Safety Endpoint', '46', '5.2.3.2.', 'Non-Key Secondary Safety Endpoints', '46', '5.2.4.', 'Secondary HR-QoL Endpoint', '46', '5.2.5.', 'Exploratory Endpoints', '46', '5.2.6.', 'PK Endpoints', '46', '6.', 'INVESTIGATIONAL PLAN', '47', '6.1.', 'Overall Study Design and Plan', '47', '6.2.', 'Crossover', '49', '6.3.', 'Data Safety Monitoring Board', '50', '6.4.', 'Independent Review Committee', '50', '7.', 'STUDY POPULATION SELECTION', '51', '7.1.', 'Study Population', '51', '7.2.', 'Inclusion Criteria', '51', '7.3.', 'Exclusion Criteria', '52', '8.', 'REGISTRATION AND RANDOMIZATION', '55', '8.1.', 'Screening and Registration', '55', '8.1.1.', 'Study Patient Number', '55', '8.1.2.', 'Rescreening', '55', '8.1.3.', 'Screen Failures', '55', '8.1.4.', 'Replacement of Patients', '55', '8.2.', 'Randomization to Study Treatment', '55', '8.3.', 'Blinding Procedures', '56', '9.', 'DISCONTINUATION CRITERIA', '57', '9.1.', 'Early Termination of the Study', '57', '9.2.', 'Discontinuation of Study Treatment and/or Withdrawal of Patients from the', 'Study', '57', '9.3.', 'End of Study Definition', '58', 'Confidential', 'Page 5', 'Version 4.0']\n\n###\n\n", "completion": "END"}